TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16321825

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 12801944

Group type: EXPERIMENTAL
Intervention: Flamingo covered Wallstent
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ultraflex covered stent
Number of subjects: 53
Study: 11011342

Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Atrial Fibrillation (AF)
Number of subjects: 583
Study: 8798372

Group type: EXPERIMENTAL
Intervention: Selective nonoperative management
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mandatory laparotomy
Number of subjects: 51
Study: 1623901

Group type: EXPERIMENTAL
Intervention: Rectal administration of 6-mercaptopurine (30 mg/m2)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral administration of 6-mercaptopurine (87.5 mg/m2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rectal administration of 6-mercaptopurine
Number of subjects: 5
Study: 6363955

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate (B)
Number of subjects: 23
Study: 30864472

Group type: EXPERIMENTAL
Intervention: Sequential IPC for 10 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-compartment IPC for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sequential IPC compared to Single-compartment IPC
Number of subjects: 20
Study: 27650094

Group type: EXPERIMENTAL
Intervention: Heyan Kuntai Capsule (HYKT)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 390
Study: 26484951

Group type: COMPARATOR
Intervention: Lower extremity venous occlusion at 100 mm Hg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lower extremity venous occlusion
Number of subjects: 19
Study: 24690625

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri DSM 17938 (1 × 10(8) colony forming units)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 22747846

Group type: EXPERIMENTAL
Intervention: SASA! intervention
Number of subjects: 1583
Study: 21050239

Group type: EXPERIMENTAL
Intervention: Vitamin D3 treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 17147966

Group type: EXPERIMENTAL
Intervention: Partner-learning group (n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Solo-learning control group (n = 65)
Number of subjects: 130
Study: 15172083

Group type: EXPERIMENTAL
Intervention: Exercise three‐times weekly over 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral oestradiol therapy for 12 weeks
Number of subjects: 75
Study: 12352236

Group type: EXPERIMENTAL
Intervention: 0.4 percent nitroglycerin ointment applied twice or three times per day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 304
Study: 9519417

Group type: EXPERIMENTAL
Intervention: Abbott IMx assay
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hybritech Tandem‐E assay
Number of subjects: 85
Study: 9815340

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Cinnarizine with domperidone
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate with caffeine
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Ginger root
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Meclozine with caffeine
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Scopolamine Transdermal Therapeutic System (TTS)
Number of subjects: 1741
Study: 2643969

Group type: EXPERIMENTAL
Intervention: 1 microgram alphacalcidol (1 alpha‐hydroxy‐vitamin D3)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29538686

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study: 28817301

Group type: EXPERIMENTAL
Intervention: Patient financial incentives
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Behavioral interventions with financial incentives
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adherence monitoring and financial incentives
Number of subjects: 30
Study: 26643558

Group type: EXPERIMENTAL
Intervention: Routine antenatal and postnatal home-based care plus screening and treatment for abnormal vaginal flora (AVF) and urinary tract infection (UTI).
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Routine antenatal and postnatal home-based care (control arm).
Number of subjects: 10000
Study: 24267622

Group type: EXPERIMENTAL
Intervention: Thermal reflective blanket
Number of subjects: 58

Group type: COMPARATOR
Intervention: No thermal reflective blanket (Control)
Number of subjects: 58
Study: 21105759

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring (HBPM)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional office BP monitoring
Number of subjects: 223
Study: 18637554

Group type: EXPERIMENTAL
Intervention: Intralesional steroid (diluted Triamcinolone acetonide)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Silicone-gel sheeting
Number of subjects: 24
Study: 16125146

Group type: EXPERIMENTAL
Intervention: STin2 10 allele presence
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: STin2 variant with family history of suicide
Number of subjects: 258
Study: 12660407

Group type: EXPERIMENTAL
Intervention: D-ribose (10 g/d for 5 d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dextrose placebo (5 g, twice daily)
Number of subjects: 19
Study: 10773058

Group type: EXPERIMENTAL
Intervention: RBCs collected from unrelated donors
Number of subjects: 40

Group type: COMPARATOR
Intervention: RBCs collected from biologic parents
Number of subjects: 40
Study: 8629917

Group type: EXPERIMENTAL
Intervention: Telephone interview using the Functional Independence Measure (FIM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-person assessment using the Functional Independence Measure (FIM)
Number of subjects: 40
Study: 1279292

Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.25 mg cilazapril + 0.5 mg cyclopenthiazide (CPTZ)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril + 0.5 mg CPTZ
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2988158

Group type: EXPERIMENTAL
Intervention: suloctidil (200 mg t.i.d.)
Number of subjects: 438

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 438
Study: 30453329

Group type: EXPERIMENTAL
Intervention: Intensive cognitive‐communication rehabilitation (ICCR) program
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study: 28982479

Group type: EXPERIMENTAL
Intervention: Nurse-led decision coaching sessions, access to DECIMS-Wiki, final physician consultation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Care as usual with access to DECIMS-Wiki
Number of subjects: 73
Study: 26720704

Group type: EXPERIMENTAL
Intervention: Real TDCS (2 mA, 20 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham TDCS
Number of subjects: 37
Study: 24670612

Group type: COMPARATOR
Intervention: Affected side GPS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Unaffected side GPS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group GPS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Affected side APS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Unaffected side APS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group APS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lower extremity asymmetry
Number of subjects: 47
Study: 22083263

Group type: EXPERIMENTAL
Intervention: Right half‐field patch treatment (n=10) for approximately 8 hours a day for 15 consecutive days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Visual scanning training (n=8) for 40 minutes every weekday in a 15 day period
Number of subjects: 18
Study: 20395128

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 7 every 3 weeks followed by concurrent paclitaxel 175 mg/m2 (day 1) and gemcitabine 1000 mg/m2 (days 1 and 8) every 3 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sequential schedule with weekly paclitaxel
Number of subjects: 54
Study: 18238836

Group type: EXPERIMENTAL
Intervention: Pentax‐AWS
Number of subjects: 203

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 203
Study: 16037481

Group type: EXPERIMENTAL
Intervention: Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos (PEDAL) group therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 29
Study: 12406527

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sham-EA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-EA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-EA
Number of subjects: 100
Study: 10567776

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH, 300 mg once daily) plus sulphadoxine-pyrimethamine (S, 500 mg/P, 25 mg once weekly)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 263
Study: 7762496

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1692533

Group type: EXPERIMENTAL
Intervention: Magnesium glycerophosphate
Number of subjects: 11
Study: 428710

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA), 750 mg/day during weight maintenance (1st month) and weight reduction (2nd month)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bile acid preparations (CDCA and Bilron) administered randomly during weight reduction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (weight maintenance with no bile acid feeding)
Number of subjects: 24
Study: 31623899

Group type: EXPERIMENTAL
Intervention: New models for estimating foetal weight (EFW) using MRI
Number of subjects: 153

Group type: COMPARATOR
Intervention: Existing model developed by Baker et al.
Number of subjects: 153
Study: 28801403

Group type: EXPERIMENTAL
Intervention: Two, 150 min, skills‐based training sessions focused on communication and behaviour change skills with between session practice.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 12
Study: 25173772

Group type: EXPERIMENTAL
Intervention: Washing without water (bed bath with disposable wash gloves)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Traditional bed bath (using soap, water, washcloths, and towels)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Washing without water
Number of subjects: 500

Group type: COMPARATOR
Intervention: Traditional bed bath
Number of subjects: 500
Study: 22464479

Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 0/1
Number of subjects: 3582

Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 2
Number of subjects: 3582

Group type: EXPERIMENTAL
Intervention: Pre-procedural TIMI flow 3
Number of subjects: 3582

Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow achievement
Number of subjects: 3582
Study: 22111802

Group type: EXPERIMENTAL
Intervention: standard care therapy over seven-days a week
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: group circuit class therapy over five-days a week
Number of subjects: 282

Group type: COMPARATOR
Intervention: usual care therapy over five-days a week
Number of subjects: 282
Study: 18154473

Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg every 12 hours for 4 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg every 12 hours and omeprazole 40 mg every 24 hours for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nelfinavir alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nelfinavir with omeprazole
Number of subjects: 20
Study: 18074761

Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (therapy suggested by attending physician)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (non-randomized studies)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mistletoe extracts Iscador (therapy)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional therapy alone (control)
Number of subjects: 198
Study: 12895618

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 0
Study: 10703459

Group type: EXPERIMENTAL
Intervention: High Protein (HP) snacks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) snacks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High Fat (HF) snacks
Number of subjects: 8

Group type: COMPARATOR
Intervention: No Snack (NS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All treatments (HP, HC, HF, NS)
Number of subjects: 8
Study: 9166037

Group type: EXPERIMENTAL
Intervention: Parental questionnaire
Number of subjects: 88

Group type: COMPARATOR
Intervention: Paediatric assessment
Number of subjects: 88
Study: 1304181

Group type: EXPERIMENTAL
Intervention: Metal matrix, large tip
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mylar matrix, light emitting wedge, large tip
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mylar matrix, light emitting wedge, small tip
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metal matrix, small tip
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dentin gingival cavosurface margin groups
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metal matrix groups
Number of subjects: 80
Study: 2580155

Group type: EXPERIMENTAL
Intervention: Atenolol (cumulative doses of 1-8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acebutolol (cumulative doses of 10-80 mg)
Number of subjects: 0
Study: 27958381

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 582

Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Suboxone) treatment
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Genotype at rs10485058
Number of subjects: 582
Study: 27956680

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (n=40, Rop group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (n=40, NS group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (Rop group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 80
Study: 24733277

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention for depression and anxiety disorders (n=92)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enhanced usual care (control group, n=91)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 183
Study: 22445052

Group type: EXPERIMENTAL
Intervention: Manual therapy intervention
Number of subjects: 100
Study: 20955499

Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 840

Group type: COMPARATOR
Intervention: HIV-uninfected infants
Number of subjects: 840
Study: 18612787

Group type: EXPERIMENTAL
Intervention: DDD‐FP (5‐FU, 320 mg/m² daily for 21 days; CDDP, 3.5 mg/m² daily for 21 days) followed by oral 5‐FU (200 mg/body daily for 2 years)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Oral 5‐FU therapy (200 mg/body daily for 2 years)
Number of subjects: 188
Study: 16026402

Group type: EXPERIMENTAL
Intervention: Surgical abortion
Number of subjects: 368

Group type: COMPARATOR
Intervention: Medical abortion
Number of subjects: 368
Study: 12052597

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 microg every 3-4 hours, with possible increase to 200 microg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 microg every 3-4 hours, with possible increase to 50 microg)
Number of subjects: 107
Study: 10672723

Group type: EXPERIMENTAL
Intervention: Amizon (anti-inflammatory interferon-inducing drug)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study: 8754965

Group type: EXPERIMENTAL
Intervention: Systemic steroids (prednisone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled steroids in typical dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Biochemical markers of bone turnover
Number of subjects: 80
Study: 1654753

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine (pH, 5.58 +/‐ 0.12)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mL of 0.5% bupivacaine + 0.6 mL of 1.4% bicarbonate (pH, 6.53 +/‐ 0.06)
Number of subjects: 40
Study: 7046412

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (150 mg/m2 daily in three divided doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tamoxifen (10 mg twice daily)
Number of subjects: 55
Study: 31674902

Group type: EXPERIMENTAL
Intervention: THA with dual mobility cup (DMC)
Number of subjects: 60
Study: 28231964

Group type: EXPERIMENTAL
Intervention: Ilizarov external fixator
Number of subjects: 27

Group type: COMPARATOR
Intervention: Retrograde intramedullary nailing (IMN)
Number of subjects: 27
Study: 26668108

Group type: EXPERIMENTAL
Intervention: Salicylic acid plasters
Number of subjects: 201

Group type: COMPARATOR
Intervention: Scalpel debridement (Control)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Dorsal/interdigital (ID) corns
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Plantar corns
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measures
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Manchester Foot Pain and Disability Index (MFPDI)
Number of subjects: 201
Study: 24533507

Group type: EXPERIMENTAL
Intervention: Topical valproic acid (sodium valproate, 8.3%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 40
Study: 22989342

Group type: EXPERIMENTAL
Intervention: More frequent follow-up (every 4 to 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard follow-up (month intervals based on age in years)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: More frequent follow-up (every 4 to 6 weeks) without epidemiology, intention to treat analysis (ITT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard follow-up (month intervals based on age in years) without epidemiology, intention to treat analysis (ITT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parental survey responses
Number of subjects: 30
Study: 20014522

Group type: EXPERIMENTAL
Intervention: Male participants rating themselves on physical attractiveness when facing male opponents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male participants rating themselves on physical attractiveness when facing female opponents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male participants' self-ratings of physical attractiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female participants' self-ratings of physical attractiveness
Number of subjects: 0
Study: 17972591

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid and as-needed beta-agonist
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dongchong xiacao capsule plus inhaled corticosteroid and as-needed beta-agonist
Number of subjects: 60
Study: 14760514

Group type: EXPERIMENTAL
Intervention: Lecithin (1.6 g/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Carnitine (500 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Carnitine plus lecithin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Carnitine and glucose drink
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 11641684

Group type: EXPERIMENTAL
Intervention: Medical evacuation of the uterus with misoprostol
Number of subjects: 218

Group type: COMPARATOR
Intervention: Routine surgical evacuation of the uterus
Number of subjects: 218
Study: 9589295

Group type: EXPERIMENTAL
Intervention: CD patients with long ileal resections
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CD patients with short ileal resections
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CD patients with long or short ileal resections
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 14
Study: 7805564

Group type: EXPERIMENTAL
Intervention: Hyperfractionated irradiation (HF) with 1.15‐1.25Gy per fraction, twice daily, total doses of 69.6 +/- 2.1Gy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hyperfractionated irradiation (HF)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional irradiation (CF) with 1.8‐2.0Gy per fraction, once a day, total doses of 63.9 +/- 1.1Gy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional irradiation (CF)
Number of subjects: 109
Study: 3385871

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31968180

Group type: EXPERIMENTAL
Intervention: Dual wavelength Er,Cr:YSGG (2 W, 20 Hz, 50 μs) and diode 940 nm (2 W, 50% DC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: XP‐Endoshaper and finisher with EDTA 17%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dual wavelength Er,Cr:YSGG (1.25 W, 50 Hz, 50 μs) and diode 940 nm (2 W, 50% DC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control irrigated with distilled water
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control irrigated with EDTA 17% and a final rinse of NaOCl 3%
Number of subjects: 40
Study: 30241913

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD) in addition to information and exercise therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no MLD)
Number of subjects: 160
Study: 29113036

Group type: EXPERIMENTAL
Intervention: Stationary cycle (CYC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional sit (SIT)
Number of subjects: 21
Study: 26303626

Group type: EXPERIMENTAL
Intervention: Overnight supplementary oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Auto-adjusting continuous positive airways pressure (APAP)
Number of subjects: 20
Study: 22710258

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reading/play activity (Control)
Number of subjects: 9
Study: 21489346

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 23